NASDAQ:EVOK Evoke Pharma (EVOK) Stock Price, News & Analysis $4.86 +0.31 (+6.81%) (As of 08/21/2024 ET) Add Compare Share Share Today's Range$4.16▼$5.2050-Day Range$4.55▼$7.3252-Week Range$3.75▼$18.60Volume255,294 shsAverage Volume24,218 shsMarket Capitalization$41.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends Get Evoke Pharma alerts: Email Address Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Evoke Pharma Stock (NASDAQ:EVOK)Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Read More EVOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EVOK Stock News HeadlinesAugust 16, 2024 | americanbankingnews.comEvoke Pharma (NASDAQ:EVOK) Coverage Initiated at StockNews.comAugust 15, 2024 | finance.yahoo.comEvoke Pharma Second Quarter 2024 Earnings: Misses ExpectationsAugust 22, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…August 14, 2024 | nz.finance.yahoo.comEVOKE PHARMA INC.DL-,0001 (EV0.F)August 14, 2024 | nz.finance.yahoo.comEVOKE PHARMA INC.DL-,0001 (EV0.MU)August 13, 2024 | globenewswire.comEvoke Pharma, Inc. Reports Second Quarter 2024 Financial ResultsAugust 12, 2024 | msn.comThe power of snake venom: The science behind nature’s deadliest toxinAugust 11, 2024 | finance.yahoo.comAuxly Cannabis Group Inc (3KF.BE)August 22, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…August 8, 2024 | globenewswire.comEvoke Pharma, Inc. Supports Gastroparesis Awareness MonthAugust 1, 2024 | uk.investing.comEvoke Pharma announces 1-for-12 reverse stock splitJuly 31, 2024 | msn.comWhy Evoke Pharma (EVOK) Stock Is VolatileJuly 30, 2024 | globenewswire.comEvoke Pharma, Inc. Announces Reverse Stock SplitJuly 26, 2024 | msn.com60 Interesting Facts From History That You May Not Find In TextbooksJuly 25, 2024 | msn.com60 Little-Known Fascinating Facts To Awaken Your Interest In HistoryJune 17, 2024 | globenewswire.comEvoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTIMay 16, 2024 | globenewswire.comEvoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) ConferenceMay 15, 2024 | finanznachrichten.deEvoke Pharma, Inc.: Evoke Pharma Reports First Quarter 2024 Financial ResultsSee More Headlines Receive EVOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evoke Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today8/22/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVOK CUSIPN/A CIK1403708 Webwww.evokepharma.com Phone(858) 345-1494FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,790,000.00 Net Margins-116.75% Pretax Margin-116.75% Return on Equity-4,908.09% Return on Assets-78.43% Debt Debt-to-Equity RatioN/A Current Ratio1.39 Quick Ratio1.32 Sales & Book Value Annual Sales$7.53 million Price / Sales5.55 Cash FlowN/A Price / Cash FlowN/A Book Value($9.26) per share Price / Book-0.52Miscellaneous Outstanding Shares8,597,000Free Float8,073,000Market Cap$41.78 million OptionableNot Optionable Beta0.38 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Matthew J. D'Onofrio MBA (Age 54)Co-Founder, CEO & Director Comp: $779.37kDr. Marilyn R. Carlson D.M.D. (Age 76)M.D., RAC., Chief Medical Officer Comp: $681.24kMr. Christopher QuesenberryChief Commercial Officer - Gimoti (TM)Key CompetitorsEyenoviaNASDAQ:EYENSatsuma PharmaceuticalsNASDAQ:STSAMarker TherapeuticsNASDAQ:MRKRAptorum GroupNASDAQ:APMContext TherapeuticsNASDAQ:CNTXView All Competitors EVOK Stock Analysis - Frequently Asked Questions How have EVOK shares performed this year? Evoke Pharma's stock was trading at $12.6036 at the start of the year. Since then, EVOK shares have decreased by 61.4% and is now trading at $4.86. View the best growth stocks for 2024 here. How were Evoke Pharma's earnings last quarter? Evoke Pharma, Inc. (NASDAQ:EVOK) released its quarterly earnings data on Tuesday, August, 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.72) by $0.21. The specialty pharmaceutical company earned $2.55 million during the quarter. Evoke Pharma had a negative trailing twelve-month return on equity of 4,908.09% and a negative net margin of 116.75%. When did Evoke Pharma's stock split? Evoke Pharma's stock reverse split on Thursday, August 1st 2024. The 1-12 reverse split was announced on Thursday, August 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split. How do I buy shares of Evoke Pharma? Shares of EVOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Evoke Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evoke Pharma investors own include Bank of Hawaii (BOH), InterDigital (IDCC), STAG Industrial (STAG), Advanced Micro Devices (AMD), Novavax (NVAX), Sorrento Therapeutics (SRNE) and Inovio Pharmaceuticals (INO). This page (NASDAQ:EVOK) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evoke Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evoke Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
